Novartis Confirms Deaths of Two Patients Treated with Gene Therapy Zolgensma

被引：37

|

作者：

Philippidis, Alex ^{[1
]}

机构：

[1] Mary Ann Liebert Inc, New Rochelle, NY 10801 USA

来源：

HUMAN GENE THERAPY | 2022年 / 33卷 / 17-18期

关键词：

D O I：

10.1089/hum.2022.29216.bfs

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

[No abstract available]

引用

收藏

页码：842 / 844

页数：3

相关论文

共 50 条

[1] The novartis approach to gene therapy
Martin J.T.
Nature Biotechnology, 1999, 17 (Suppl 4) : 27 - 27
[2] GENE THERAPY Novartis to acquire ocular gene therapy firm
McCoy, Michael
CHEMICAL & ENGINEERING NEWS, 2022, 100 (01) : 17 - 17
[3] GENE THERAPY Novartis to acquire AveXis
Cross, Ryan
CHEMICAL & ENGINEERING NEWS, 2018, 96 (16) : 11 - 11
[4] Zolgensma - One-Time Gene Therapy for Spinal Muscular Atrophy
不详
MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2019, 61 (1577): : 113 - 114
[5] Novartis grows its gene therapy ambitions
Asher Mullard
Nature Reviews Drug Discovery, 2018, 17 : 307 - 307
[6] GENE THERAPY Novartis is eyed for data manipulation
Cross, Ryan
CHEMICAL & ENGINEERING NEWS, 2019, 97 (32) : 15 - 15
[7] Novartis grows its gene therapy ambitions
Mullard, Asher
NATURE REVIEWS DRUG DISCOVERY, 2018, 17 (05) : 307 - 307
[8] Novartis licenses gene therapy to avoid monopoly
Vicki Glaser
Nature Biotechnology, 1997, 15 : 118 - 119
[9] Novartis licenses gene therapy to avoid monopoly
Glaser, V
NATURE BIOTECHNOLOGY, 1997, 15 (02) : 118 - 119
[10] Novartis gene therapy assets under scrutiny
不详
EUROPEAN CHEMICAL NEWS, 1996, 66 (1734): : 4 - 4

← 1 2 3 4 5 →